Zobrazeno 1 - 10
of 58
pro vyhledávání: '"KATHERINE S. TWEDEN"'
Autor:
Scott A. Shikora, Bruce M. Wolfe, Caroline M. Apovian, Mehran Anvari, David B. Sarwer, Robert D. Gibbons, Sayeed Ikramuddin, Christopher J. Miller, Mark B. Knudson, Katherine S. Tweden, Michael G. Sarr, Charles J. Billington
Publikováno v:
Journal of Obesity, Vol 2015 (2015)
Background/Objectives. Vagal block therapy (vBloc) is effective for moderate to severe obesity at one year. Subjects/Methods. The ReCharge trial is a double-blind, randomized controlled clinical trial of 239 participants with body mass index (BMI) of
Externí odkaz:
https://doaj.org/article/198d9b1a2ab5403b9a5f30294fb42ba6
Autor:
ARNAUD E. JACQUIN, LUJAIN AL-KHAWI, PATRICIA SANCHEZ, SANAT MOHANTY, KATHERINE S. TWEDEN, FRANCINE R. KAUFMAN
Publikováno v:
Diabetes. 71
Background: The PROMISE Clinical Trial, conducted to assess safety and accuracy of a 180-day implantable CGM System, had 43 subjects implanted with a modified sensor containing sacrificial boronic acid (SBA) to reduce the degradation of the boronic a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17ac4db8da3e6edac286a9e11b13a9a7
https://doi.org/10.2337/db22-655-p
https://doi.org/10.2337/db22-655-p
Autor:
VENKATA N. VELVADAPU, JAMES M. MASCIOTTI, ANDREW D. DEHENNIS, PATRICIA SANCHEZ, KATHERINE S. TWEDEN, FRANCINE R. KAUFMAN, SORIN IOACARA
Publikováno v:
Diabetes. 71
Background: The Eversense CGM System sensor is implanted in the upper arm. It uses a fluorescent, boronic acid glucose-binding moiety to measure glucose. The glucose indicator is susceptible to oxidative de-boronation from reactive oxygen species (RO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::447848ef20d230dd08ecb99b58399cd1
https://doi.org/10.2337/db22-691-p
https://doi.org/10.2337/db22-691-p
Autor:
ARNAUD E. JACQUIN, LUJAIN AL-KHAWI, SAMANWOY GHOSH-DASTIDAR, KATHERINE S. TWEDEN, FRANCINE R. KAUFMAN
Publikováno v:
Diabetes. 71
Background: The PROMISE Clinical Study was conducted to determine the accuracy and safety of the next generation implantable CGM System. A subset of 43 subjects had a sensor implanted with modified chemistry referred to as sacrificial boronic acid (S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c255ae5de309cdb2fa448651b87fad5a
https://doi.org/10.2337/db22-656-p
https://doi.org/10.2337/db22-656-p
Autor:
Concetta Irace, Linda Tartaglione, Katherine S. Tweden, Francine R. Kaufman, Agostino Gnasso, Annamaria Nuzzi, Giuseppe Citro, Luigi Laviola, Sergio Di Molfetta, Dario Pitocco, Elisabetta Lovati, Roberta Assaloni, Antonio Cutruzzolà, Angelo Cignarelli, Barbara Brunato
Publikováno v:
Diabetes, Obesity & Metabolism
Aims This real‐world study evaluated the changes in glycated haemoglobin (HbA1c) and continuous glucose monitoring (CGM) metrics associated with use of the implantable 180‐day Eversense CGM System (Eversense) in patients with type 1 diabetes. Mat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef7ed0c63cc344dadc26651f47372f51
http://europepmc.org/articles/PMC7317779
http://europepmc.org/articles/PMC7317779
Publikováno v:
Diabetes Technology & Therapeutics
Previously, the safety and accuracy of the Eversense continuous glucose monitoring (CGM) system were characterized in three pivotal trials among individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D) with a single 90- or 180-day sensor inse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ec028671e5fcd4e726bc142171603eb
https://doi.org/10.1089/dia.2019.0159
https://doi.org/10.1089/dia.2019.0159
Publikováno v:
Diabetes Technology & Therapeutics. 21:677-681
Background: The Eversense® Continuous Glucose Monitoring (CGM) System, with the first 90-day implantable sensor, received FDA (Food and Drug Administration) approval in June 2018. No real-...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6499f336a43e681258e478bc092ce4d6
https://doi.org/10.1089/dia.2019.0234
https://doi.org/10.1089/dia.2019.0234
Publikováno v:
Expert review of medical devices. 18(10)
Continuous glucose monitoring (CGM) systems offer real-time data to facilitate diabetes management. The novel Eversense CGM has been approved in Europe and the US. The unique characteristics are the fully implantable sensor and the sensor life up to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70056c85e3fe1d33119169dd0625218a
https://pubmed.ncbi.nlm.nih.gov/34528851
https://pubmed.ncbi.nlm.nih.gov/34528851
Autor:
Mark P. Christiansen, Timothy S. Bailey, Anna R Chang, David R. Liljenquist, Katherine S. Tweden, Francine R. Kaufman, Bruce W. Bode, Ronald L. Brazg, Andrew Dehennis, Halis Kaan Akturk, Satish K. Garg, Douglas S Denham
Publikováno v:
Diabetes Technology & Therapeutics
Background: Use of continuous glucose monitoring (CGM) systems is being rapidly adopted as standard of care for insulin-requiring patients with diabetes. The PROMISE study (NCT03808376) evaluated the accuracy and safety of the next-generation implant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c7c7812c5e776be19b3d74b730237ba
https://pubmed.ncbi.nlm.nih.gov/34515521
https://pubmed.ncbi.nlm.nih.gov/34515521
Autor:
David R. Liljenquist, Timothy S. Bailey, Francine R. Kaufman, Mark P. Christiansen, Satish K. Garg, Halis Kaan Akturk, Douglas S Denham, Andrew Dehennis, Bruce W. Bode, Katherine S. Tweden, Ronald L. Brazg, Anna Chang
Publikováno v:
Diabetes. 70
Background: The prospective, multi-center PROMISE study evaluated the safety and accuracy of the next generation Eversense CGM System for up to 180 days in 181 adults with diabetes at 8 US clinical sites. Methods: Accuracy was evaluated by comparing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d117607bfc477e210c9d74186a1179ef
https://doi.org/10.2337/db21-149-or
https://doi.org/10.2337/db21-149-or